Update shared on06 Aug 2025
Fair value Increased 0.25%Esperion Therapeutics' consensus price target has increased as analysts now assign a higher future P/E despite a decline in net profit margin, resulting in the APT rising from $5.79 to $6.50.
What's in the News
- Esperion Therapeutics was dropped from the S&P Pharmaceuticals Select Industry Index.
- Entered into a license and distribution agreement with HLS Therapeutics, granting exclusive commercialization rights for NEXLETOL and NEXLIZET in Canada; Esperion will receive an upfront payment, milestone payments, tiered royalties, and supply the finished product at a profitable transfer price.
Valuation Changes
Summary of Valuation Changes for Esperion Therapeutics
- The Consensus Analyst Price Target has significantly risen from $5.79 to $6.50.
- The Future P/E for Esperion Therapeutics has significantly risen from 21.59x to 56.29x.
- The Net Profit Margin for Esperion Therapeutics has significantly fallen from 14.49% to 6.69%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.